Skip to main content

CCTG Connection



Published:
Category: Group updates
CCTG is recruiting for a Patient Representative to support the Gynecology Committee

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gynecology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gynecology Disease Site Committee, the Gynecology Disease Site Executive Committee, and the CCTG Patient Representative Committee.

Read More

Published:
Category: Trials
A new multiple myeloma trial assessing the duration of treatment injections has opened in Canada

The CCTG MY13 trial is a phase III non-inferiority randomized controlled trial of fixed duration versus continuous daratumumab among transplant in eligible older adults with newly diagnosed multiple myeloma.

There is little scientific evidence around the effective timing of injectable treatments for multiple myeloma. These patients receive treatment with three medicines - two tablets and an injection - all continued indefinitely until they stop working, or the side effects become unmanageable. 

Read More



Published:
Category: Group updates
Patient Representative Suzanne Wood
CCTG would like to extend a warm welcome to Patient Representative Suzanne Wood who will be supporting the GI disease site committee. Suzanne is from Toronto and was diagnosed with Stage IV Colon cancer in July 2022.
Read More

Published:
Category: Group updates
the Frances A Shepherd Award

The Frances A Shepherd Award is for investigators or post-graduate trainees, traveling to present CCTG related work at major international meetings. Each award will be approximately $1000 and offered two to three times a year. Applicants who have had their research accepted for oral or poster presentation at an international scientific meeting and have not received another award to support their travel are eligible to apply. The application deadline will be set in the spring and fall to coincide with the major international cancer conferences.

Read More

Published:
Category: Group updates
For the Gynecology Disease Site Committee

Clinical Research Associate Volunteer needed for the Gynecology Disease Site Committee

The Canadian Cancer Trials Group is actively seeking a CRA representative from Canadian Member sites to sit on the Gynecology Disease Site Committee.

Read More

Published:
Category: Publications
An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared with Conventional Palliative RT for Spinal Metastases and a Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer Read More

Published:
Category: Publications
ALC3 primary publication: A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for Acute Myeloid Leukemia
 
Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Appelbaum FR, Erba HP. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 38: 58-66.
Read More

Published:
Category: Trials
Closed to Accrual: PR21

The PR.21 study: A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has closed to accrual as the accrual target has been met.

Read More